Biogen (NASDAQ:BIIB) is gearing up to announce its quarterly earnings on Thursday, 2025-10-30. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results , but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share was 22.1% above analysts’ consensus ...

Providing a diverse range of perspectives from bullish to bearish, 19 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months. The table below provides a concise overview of ...

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI ® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE ® ...

For the full-year 2024, Biogen revenues amounted to $9.7bn, down 2% year-on-year, while GAAP diluted EPS was up 40%, to $11.21, and non-GAAP EPS $16.47, up 12% year-on-year. In terms of guidance for ...

AI-generated summary reviewed by our newsroom. Read our AI Policy. Biogen plans to beef up its Research Triangle Park operations with $2 billion in new local spending, the company announced Monday.

Analysts' ratings for Biogen (NASDAQ:BIIB) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table summarizes their recent ratings, shedding light on the ...

CAMBRIDGE — Biogen on Tuesday held a ceremonial groundbreaking of its 16-story headquarters in Kendall Square, ushering in the latest phase of the neighborhood’s transformation from “Nowhere Square” ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Since its approval in 2023, the ...

With its move to MIT’s Volpe Center in Kendall Square, the drugmaker is consolidating its local footprint from three buildings to one In the first major deal at MIT’s ambitious overhaul of the old ...